Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
WRAP UP BREAST CANCER Stefania Redana Divisione Universitaria di Oncologia Medica IRCC - Candiolo Bologna, 20 Giugno 2010 Wrap Up Breast Cancer Outline • Loco-regional treatment – – • Endocrine therapy – • The role of sentinel node dissection in clinically N0 patients Radiotherapy: time for changing clinical practice? Chemopreservation of ovarian function Metastatic disease – – – – – HER2 positive disease: beyond trastuzumab and lapatinib Biopsy of metastatic sites Multi-targeted therapies Role of bevacizumab in first line treatment New drugs Loco-regional treatment The role of sentinel node dissection ACOSOG Z0010 A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. Abs CRA 504 SN not found cT1 or cT2 N0 M0 R E G I S T E R E D BCT, SLND, bilateral iliac crest BM aspiration YES: enrolled in Z0011 SN positive SN negative N=5210 ALND Consent for Z0011 IHC NO NO ALND and no specific axillary therapy F O L L O W E D Loco-regional treatment The role of sentinel node dissection ACOSOG Z0010: main results – – – – 5 years overall survival: 93% among patients with H&E+ SN The detection of IHC+ SN mets has no impact on overall survival The detection of IHC+ bone marrow mets is predictive for a reduced overall survival No clinical implication on daily clinical practice Loco-regional treatment The role of sentinel node dissection cT1 or cT2 N0 M0 ACOSOG Z0011 A radomized trial of axillary node dissection in women with clinical T1/T2 N0 M0 breast cancer who have a positive sentinel node. Abs CRA 506 BCT, SLND with positive SN N=891 of the planned 1900 R A N D O M ALND Breast radiation NO furhter surgery Adjuvant Systemic therapy F O L L O W E D Loco-regional treatment The role of sentinel node dissection ACOSOG Z0011: main results – No difference in the rate of local recurrence between ALND and SLND (4.1% vs 2.8%, respectively) – Loco-regional recurrence rate is independent from the number of nodes removed, positive nodes or the size of nodal disease – No impact on disease free survival (83.2% vs 82.2% in SLND and ALND respectively) – No impact on overall survival (92.5% vs 91.8% in SLND and ALND respectively) – Hard to believe that 0.9% increased risk of regional recurrence and 2.8% increased risk of loco-regional recurrence might influence survival Loco-regional treatment The role of sentinel node dissection NSABP B32 A randomized phase III clinical trial to compare sentinel node resection to axillary dissection in clinically node-negative breast cancer patients. Abs LBA 505 Clinically negative node disease R A N D O M SLND + ALND SLND SLND positive SLND negative Intraop cytology and postop H&E FOLLOW-UP N=1975 SLND positive SLND negative FOLLOW-UP N=2011 Loco-regional treatment The role of sentinel node dissection NSABP B32: main results – – – – No difference in the rate of local (2.7% vs 2.4%) and axillary recurrence (0.1% vs 0.3%) between ALND and SLND No impact on disease free survival (HR 1.05, p=0.542), no difference even according to stratification factors (type of surgery, tumor size, age) No impact on overall survival (HR 1.20, p=0.117), no difference even according to stratification factors (type of surgery, tumor size, age) More morbidty was seen after ALND Loco-regional treatment Radiotherapy: time for changing clinical practice? CALGB 9343 comparison of lumpectomy plus tamoxifen with or without irradiation in women 70 or older with stage I, ER+ breast carcinoma. Abs 507 Age≥70 Clinically node negative Lumpectomy, negative margins Tumor size ≤2cm ER positive or indeterminate R A N D O M I Z A T I O N TAMOXIFEN + RADIATION THERAPY TAMOXIFEN + NO RADIATION THERAPY N=631 Median follow-up 12 years Loco-regional treatment Radiotherapy: time for changing clinical practice? CALGB 9343: main results Breast recurrence Ultimate breast preservation Secondary primary Distant metastaes Breast cancer specific death (3%) Death from any cause (46%) ~7% NS NS NS NS NS Endocrine therapy Chemopreservation of ovarian function Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. Abs 528 281 pt Age 18-45 Stage I-III HR + or - R A N D O M CHT 133 CHT + OS 148 Main Results Early menopause No menopause CT 32.3% 58% CT + T 13.5% 77% Absolute reduction of early menopause: ~19% Metastatic disease HER2 positive breast cancer A phase Ib/II trial of trastuzumab-DM1 (TDM-1) with pertuzumab for women with HER2 positive locally advanced or metastatic breast cancer who were previously treated with trastuzumab. Abs 1012 Metastatic disease HER2 positive breast cancer Efficacy results Cohort 1 (n=3) Complete response Cohort 2 (n=25) Total (n=28) 0 0 0 Partial response 2 (66.7%) 8 (32%) 10 (35.7%) Stable disease 1 (33.3%) 12 (48%) 13 (46.4%) Progressive disease 0 4 (16%) 4 (14.3%) Missing 0 1 (4%) 1 (3.6%) Safety Results 1 grade 5 event 2 grade 4 evets (4.5%) Most common grade 3 events were: fatigue (13.6%), thrombocytopenia (6.8%), increase of AST (6.8%), nausea and vomiting (4.5% each) Metastatic disease Biopsy of metastatic sites Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. Abs 1007 Recurrence or progression • DESTINY STUDY • Single institution study (Canada) • ER/PgR determined according to ASCO guidelines with IHC • HER2 FISH • Re analysis of primary Written informed consent Oncologist post-biopsy questionnaire • BRITS STUDY • Multicentric study (UK) • ER/PgR determined with IHC according to Allred score • HER2 FISH • Re analysis of primary N=271 patients BIOPSY Central revision of ER/PgR/HER2 Oncologist post-biopsy questionnaire Metastatic disease Biopsy of metastatic sites Should liver metastases of breast cancer be biopsied to improve treatment choice? Abs CRA 1008 – – TRIAL DESIGN: retrospective analysis on 255 liver biopsy performed on metastatic recurrent breast cancer at a single institution AIM: quantify discordance of ER, PgR and HER2 expression between primary tumor and metastases from breast cancer Discordance in hormone receptor status in breast cancer during tumor progression. Abs 1009 – – TRIAL DESIGN: retrospective analysis of 486 patients for whom assessment of ER and PgR was available on both primary tumor and mets AIM: determine if hormone receptors (ER and PgR) change between the primary tumor and recurrence Metastatic disease Biopsy of metastatic sites AMIR LOCATELLI KARLSSON LITTERATURE Overall discordance (%) 38.8 N.R. N.R. 29% (17.7-55) Overall ER discordance (%) 12.6 14.5 35 N.R. ER gain (%) 14.0 25.9 8 N.R. ER loss (%) 12.1 11.2 27 N.R. Overall PgR discordance (%) 34.1 48.6 43 N.R. HER2 gain (%) 4.6 5.9 N.R. N.R. HER2 loss (%) 12.5 31.5 N.R. N.R. Change in treatment decision 15% 12% N.R. N.R. Amir: less discordance among triple negative tumors (6.8%) Karlsson: correlation between ER status in relapse and OS Metastatic disease Multi-targeted therapies SUN 1064. Sunitinib (SU) in combintion with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). Abs LBA 1010 SUN 1099. Phase III trial of Sunitinib (SU) in cmbination with capecitabine (C) versus C alone in previously treated advanced breast cancer (ABC). Abs LBA 1011 SUN 1064 Measurable or non measurable disease ≥12 months from neo/adjuvant taxanes No CHT for ABC Primary End Point: PFS R A N D O M D+ SUN D Measurable or SUN 1099 non measurable disease Prior neo/adjuvant anthracyclines and taxanes 1-2 prior CHT for ABC R A N D O M Secondary: ORR, OS,safety C+ SUN C Metastatic disease Multi-targeted therapies Efficacy results SUN 1064 • Safety results • • SUN 1099 D+ SUN D C+ SUN C PFS (months) 8.7 8.3 5.5 5.9 HR (95% IC) 0.92 (0.721.19) P=0.904 ORR (%) 55 42 54 59 24.8 25.5 16.4 16.5 OS (months) 1,22 (0.95-1.58) P=0.941 Most grade 3-4 AE were registered in the experimental arms More frequent AE were: neutropenia, thrombocytopenia, asthenia/fatigue, diarrhea, HFS, nausea and vomiting Metastatic disease Role of bevacizumab in first line therapy A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy for treatment of patients with metastatic breast cancer(MBC). Abs 1005 E2100 Paclitaxel Previously untreated MBC AVADO Docetaxel RIBBON-1 Capecitabine, anthracyclines or taxanes R A N D O M I Z E CT + NO BV Treat untill PD CT + BV PRIMARY END POINT: PFS Optio nal 2nd line with BV Metastatic disease Role of bevacizumab in first line therapy Main results No BV (1008) AVADO E2100 Median PFS (months) HR (95% IC) Median PFS OS NO BV BV 6.7 NO BV 5.8 11.3 7.926.4 Stratified HR (95% HR IC) P valuesurvival (%) 1 year 0.48 (0.39-0.61) Median ORR* FU for OS 35 P<0.0001 BV (1439) RIBBON-1 Capecitabine BV 8.8 BV BV 0.64NO (0.57-1,07) 5.7 8.6 0.62 (0.48-0.79) 0.97 (0.86-1.08) 0.69 (0.56-0.84) P=0.0003 P=0.0002 77 29 32% * Only patients with measurable disease 23 RIBBON-1 Anthra/Tax 9.2 NO BV BV 9.2 26.78.0 0.64 (0.52-0.80) 82 P<0.0001 49% 26 Metastatic disease New drugs A Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Abs CRA1004^ Metastatic disease New drugs Efficacy results Eribulin Median OS (months) TPC 13.12 HR (95% IC) 0.81 (0.66-0,99) 1 year survival (%) 53.9 43.7 Median PFS (months) 3.7 2.2 HR (95% IC) ORR (%) Clinical benefit (CR + PR + SD≥6 months) (%) Safety results 10.65 Adverse Events (%) 0.87 (0.71-1.05) 12 4.7 22.6 16.8 Eribulin (503) TPC (247) All AE 98.8 93.1 Serious AE 25.0 25.9 Fatal AE 4.0 7.3 Take home messages Early Breast Cancer 1. 2. 3. 4. Patients with early breast cancer clinically N0 should not undergo ALND but only SLND Patients with clinically N0 but positive SLND could safely be spared ALND without an increased risk of progression or death Old women with HR+, cN0, free margins after lumpectomy could be spared RT if given hormonal therapy Young women should be offered OS during adjuvant chemotherapy either they are HR+ or not Take home messages Metastatic disease 1. 2. 3. 4. 5. TDM-1 + Pertuzumab is a reasonable option for patients with HER2+ disease progressing after trastuzumab and lapatinib Biopsy of metastatic sites could be changing practice Sunitinib should not be considered for the treatment of ABC 1st line bevacizumab increases PFS and ORR but has no effect on OS (hard to see in 1st line treatments) Eribulin increases OS in heavily pre-treated metastatic breast cancer patients (new drugs can impact OS in further lines of therapy)